Manila Times Business
Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease
Phase 4 ELEVATE-PD interim data from the entire study population (n=214) continue to show clinically meaningful, consistent benefits of CREXONT across all prior treatment groupsSubstantial increases in daily "Good On” time, reductions in "Off” time, and meaningful improvements in motor function were observed after switching to CREXONT®Patients switching to CREXONT® from RYTARY® gained 3.03 hours of additional daily "Good On” time and nearly doubled the duration of continuous "Good On” intervals,
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
BC-Driven Breakthrough: TCL Solar's Value Leap from Wafer Leadership to Tier 1 Module Supplier
2h ago
Making Sustainability Count on World Environment Day: How Beko Focuses on Lowering Water and Energy Consumption from Factories to Homes
2h ago
Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML
2h ago
PropMarket Launches as the First Prop Firm Built for Prediction Markets
2h ago